Kura Oncology (KURA) Non-Current Deffered Revenue (2024 - 2026)

Kura Oncology (KURA) has 3 years of Non-Current Deffered Revenue data on file, last reported at $416.7 million in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 53.26% year-over-year to $416.7 million in Q1 2026; TTM through Mar 2026 was $416.7 million, a 53.26% increase from a year earlier, with the FY2025 full-year figure at $424.9 million, up 67.35% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $416.7 million, down from $424.9 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for KURA reached as high as $424.9 million in Q4 2025 and fell as low as $252.5 million in Q2 2025.
• Historically, Non-Current Deffered Revenue has averaged $314.8 million across 3 years, with a median of $270.4 million in 2025.
• Across the five-year window, Non-Current Deffered Revenue soared 67.35% in 2025 and surged 53.26% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $253.9 million in 2024, then surged by 67.35% to $424.9 million in 2025, then declined by 1.92% to $416.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $416.7 million in Q1 2026, $424.9 million in Q4 2025, and $268.9 million in Q3 2025.